COVID-19: Protection of IP for AI tools

Nine days before the World Health Organization officially notified the public of a flu-like outbreak in China, BlueDot, a Canadian artificial intelligence (AI) startup, warned its clients of a potential outbreak near a market in Wuhan, China.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

‘Blatant imitation’: Indian court blocks copycat pharma branding

22 June 2026 The court granted Blue Cross Laboratories a permanent injunction after finding that a rival product’s mark and packaging closely mirrored its own.

Asia

Takeda’s China IP head: What pharma is still getting wrong

27 May 2026 China’s IP system is undergoing real change. Takeda’s IP head for the region explains what that looks like on the ground and why the old playbook no longer cuts it.

Asia

WATCH: China patent landscape

24 May 2026 The regulatory and IP environment in China is shifting at a rapid pace, bringing new measures, guiding cases, and compliance hurdles. This session provides a high-level overview of the past year’s critical changes and what life sciences companies must anticipate on the horizon.

More features

Masimo keeps $634m smartwatch award and moves to appeal

Arbutus takes Comirnaty LNP patent fight to Canada and UPC

Why is 2026 already a record year for M&A activity?

Illumina ordered to recall products after German patent ruling

Goodwin launches San Diego office with senior life sciences hire

Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer

UK-Switzerland strike trade deal with first-of-its-kind pharma rules

Interview: How BlueRock Therapeutics is layering IP in stem cell therapies

COVID-19: Protection of IP for AI tools

More on this story

Editor's picks

Editor's picks

More features